ReportGem ReportGem

U.S. COMPANY FILING

GILEAD SCIENCES, INC. — Form 10-Q filed 2026-05-07

Filed: 2026-05-07Company: GILEAD SCIENCES, INC.Ticker: GILDExchange: NasdaqForm: 10-QReport period: 2026-03-31SEC accession: 0000882095-26-000024Event: earningsMateriality: 85

Filing text preview

Gilead's Q1 2026 revenue rose 4.4% to $6.96B, net income surged 53.7% to $2.02B. Announced acquisitions: completed Arcellx for ~$7.1B, agreed to acquire Tubulis (~$3.2B) and Ouro Medicines (~$1.7B). Operating cash flow increased to $2.54B. EPS $1.63 basic, $1.61 diluted.

This preview uses text already stored in ReportGem and does not fetch the document from object storage during SEO generation. Review the internal filing record and the official SEC source before relying on it.

Open filing record

Related research and intelligence

Official SEC filing2026-05-07Top economists warn of wealth inequality in U.S. surpassing Gilded Age2026-08-19FORM 10-Q2026-08-06 · 10-QFORM 8-K2026-08-04 · 8-KFORM 8-K2026-05-07 · 8-KFORM 10-K2026-02-24 · 10-KFORM 8-K2026-02-10 · 8-KFORM 10-Q2025-11-07 · 10-Q